Streetbeat News

Earnings

ADBE

Adobe (NASDAQ:ADBE) received mixed analyst ratings in the latest quarter with 22 analysts providing insights. The average 12-month price target was adjusted to $621.14 from $660.10, indicating a 5.9% drop. Analysts' actions varied, with some maintaining their ratings and price targets, while others adjusted them up or down based on market conditions and Adobe's performance. Adobe's financial indicators show solid revenue growth but below industry standards in net margin, ROE, and ROA, suggesting challenges in profitability and asset utilization.

Portfolio Pulse from Benzinga Insights

March 27, 2024 | 12:00 pm

OSA

ProSomnus (NASDAQ:OSA) reported Q4 sales of $7.84M, surpassing the $7.37M estimate, marking a 6.35% beat and a 35.32% increase from last year's $5.79M.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 12:00 pm

FR

Six analysts have recently updated their ratings on First Industrial Realty (NYSE:FR), showing a mix of bullish to bearish sentiments. The average 12-month price target for FR has been raised to $56.00, up 4.34% from the previous $53.67. Analyst actions include both upgrades and downgrades, with price targets ranging from $47.00 to $60.00. First Industrial Realty, a real estate investment trust, has shown strong financial performance with notable revenue growth, high net margin, and efficient asset and equity management.

Portfolio Pulse from Benzinga Insights

March 27, 2024 | 12:00 pm

LE

Lands' End shares experienced an increase following the announcement of their fourth-quarter results, which surpassed expectations.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 11:58 am

LIDR

AEye reported worse-than-expected Q4 revenue results, leading to a decrease in its share price.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 11:55 am

VLD

Velo3D's stock price declined following the announcement of disappointing Q4 financial results, which fell short of expectations.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 11:42 am

PDSB

PDS Biotechnology (NASDAQ:PDSB) reported a Q4 EPS loss of $(0.35), surpassing the $(0.44) analyst consensus estimate. This represents a 47.76% improvement over the previous year's $(0.67) per share loss. The company's cash balance stands at $56.6M.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 11:38 am

EVAX

Evaxion Biotech (NASDAQ:EVAX) reported a Q4 EPS of $(0.16), surpassing the $(1.60) estimate, marking a 90% beat and a 94.48% improvement from last year's $(2.90) per share loss. Sales reached $73.00K.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 11:34 am

SYRS

Syros Pharmaceuticals (NASDAQ:SYRS) reported a significant miss in both earnings and revenue for Q4. EPS was $(2.22), missing estimates by 94.74%, and sales were $386.00K, missing estimates by 80.70%. This represents a drastic decrease in earnings and a significant increase in sales from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 11:31 am

PAYS

PaySign shares surged following the announcement of their Q4 financial results, which exceeded market expectations.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 11:31 am